2617TransThera Sciences (Nanjing), Inc.

🇭🇰 Hong Kong Borsası
8.54
HKD
Analysis Scores
Lothien Robustness Score?
31/100
Weak
Neden bu skor?
Damodaran ?
-
Damodaran skoru hesaplanamadı
Dalio Risk ?
87/100
Piotroski ?
3/9
Weak
revenue data missing → margin comparison unavailable (C8)
Graham ?
Negatif HBK
Company is loss-making (EPS = -0.8766 TL) — Graham formula requires positive earnings
Active Metric?
1/4
Confidence?
48%
Lothien Robustness Summary
42/100
Lothien Sağlamlık: Zayıf (42/100)
Olumsuz göstergeler ağır basıyor. Finansal yapıda zayıflıklar mevcut. | Kısa Vade: Nötr | Uzun Vade: Nötr | Pozitif: 3 | Negatif: 2 | Nötr: 2
Net Zarar
Son çeyrekte -HK$87M zarar açıklandı. Yatırımcı dikkatli olmalı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%+0.0). İstikrarlı seyir.
Net Nakit Pozisyonu
Şirketin nakdi borçlarından HK$486M fazla. Borç riski düşük.
Güçlü Likidite
Cari oran 3.87x — kısa vadeli borçları rahat karşılıyor.
Yüksek PD/DD
PD/DD: 5.45. Piyasa defter değerinin çok üstünde fiyatlıyor. Büyüme beklentisi primli.
Negatif ROE
ROE: %-35.5. Şirket özsermayesini eritiyor.
Sonraki Çeyrek: Artış Beklentisi
Pusla tahminine göre bir sonraki çeyrekte kâr %+39.9 artabilir (-HK$87M → -HK$52M).

Data date 2026-10-22 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-10-22
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Çok Yüksek
252 days
Annual Volatility ?
%124.3
VaR 95% ?
%13.58
daily max loss
VaR 99% ?
%18.92
daily max loss
CVaR 95% ?
%14.23
expected loss (tail)
Max Drawdown ?
%96.3
10.11.2025 → 22.10.2026
Skewness ?
0.76
Parametrik%13.58
Historik%7.28
Cornish-Fisher%8.08
Return Distribution
Valuation
Potential?
-29.4%
Debt Cycle?
Early Expansion
Balance Sheet Analysis? Q2026/6
Son 6 çeyrek ardışık zarar
Fiyat TRAMA-99 altında: %-17.0 — teknik trend olumsuz
Direnç seviyesi: TRAMA-99 = 10.29 HKD
Fundamental & Technical Analysis
Profitability
ROE - Return on Equity (TTM) %-35.5
ROE %-35.5 — negative return on equity.
Valuation
P/B Ratio 5.45x Sector: 2.37x
PD/DD 5.45x — sector median's %130 above. Expensive book value.
Indebtedness
Current Ratio 3.87x
Current ratio 3.87x — current assets are 2x short-term liabilities. Very healthy liquidity.
Debt / Equity 0.00x
Low leverage — majority of assets financed by equity.
Interest Coverage -2944.7x
Interest coverage -2944.7x — critical level. Risk of difficulty in interest payments.
Growth
Net Profit Growth (YoY) %-7.8
Loss %7.8 increased — losses deepening.
Score Explanations
Lothien Robustness
31/100
Weak robustness (31/100). Valuation metrics and/or debt profile are unfavorable; caution is needed.
Weak
Potential
-29.4%
Minus %29.4 expected value (6.02) vs current price comparison. 1/4 valuation models could be calculated. Model confidence %48.
Components: P/B target: 3.31
Dalio Risk Analysis
87/100
Low debt risk (87/100). Interest coverage ratio -2944.7x — weak, fragile.
Leverage: 100/100 | Debt Service: 100/100 | Quality: 33/100
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
3/9
Weak Piotroski (3/9). Many balance sheet quality criteria not met. Note: revenue data missing → margin comparison unavailable (C8)
Weak
Graham Intrinsic Value
—
Company is loss-making (EPS = -0.8766 TL) — Graham formula requires positive earnings
⚖️ Sector Comparison
P/B Ratio
5.45x vs 2.37x
Compared to sector %130 more expensive (by book value)
TRAMA-99 Trend — Strong Downtrend
Price (8.54), TRAMA-99 line's %17.0 below. Significant downtrend. TRAMA line acts as strong technical resistance.
Price:: 8.54
TRAMA: 10.29
Difference: %-17.0
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
P/E Ratio ?
P/B Ratio ?
EBITDA ?
Net Working Capital ?
Current Ratio ?
2617 — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.